Quick summary
Palmitoyl Tripeptide-38 (MATRIXYL synthe'6) is a matrikine-mimetic signal peptide that simultaneously stimulates six key ECM components including collagen I, IV, fibronectin, and hyaluronic acid. Clinical studies showed up to 31% wrinkle depth reduction in 2 months at 2% concentration.
Overview
Palmitoyl Tripeptide-38 is a matrikine-mimetic signal peptide derived from tripeptide KMK found naturally in collagen VI and laminin. It is a palmitoylated lipopeptide used in anti-aging cosmeceutical formulations for its ability to simultaneously stimulate six key components of the dermal extracellular matrix, making it one of the most comprehensive skin-regenerating peptides available.
Mechanism of action
Palmitoyl Tripeptide-38 acts as a matrikine mimic, sending biological signals to dermal fibroblasts to upregulate synthesis of collagen I, II, and IV, fibronectin, hyaluronic acid, and laminin-5. The palmitoyl fatty acid chain enhances skin penetration through the lipophilic stratum corneum. Once in the dermis, the peptide activates fibroblast collagen-synthesis pathways and supports ECM remodeling at the dermal-epidermal junction. It also modulates wound repair signaling and promotes tissue regeneration without irritating the epidermis.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| anti-aging / wrinkle reduction | topical | 1–3 % | once or twice daily | Used at 1-3% concentration in serum or cream formulations. Apply to cleansed skin. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
In vitro studies confirm stimulation of six major ECM proteins simultaneously. A 2-month clinical study using 2% active concentration showed up to 31% reduction in wrinkle depth in women. A face serum study combining Palmitoyl Tripeptide-38 with hydrolyzed hyaluronic acid and bakuchiol demonstrated significant improvements in skin quality scores. All evidence is cosmetic/in vitro; no published RCTs as of 2026.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Palmitoyl Tripeptide-38 for synergistic effects.
Legal status
Approved cosmetic ingredient used globally in OTC skincare formulations. No prescription or regulatory approval required. Subject to standard cosmetic ingredient safety review.
Sourcing & access
Research compound
Palmitoyl Tripeptide-38 is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Palmitoyl Tripeptide-38, marketed as MATRIXYL synthe'6, is a lipopeptide consisting of a tripeptide sequence derived from the KMK domain of collagen VI and laminin. It is designed to simultaneously stimulate six extracellular matrix proteins rather than targeting a single protein. The palmitoyl fatty acid chain conjugated to the peptide enhances penetration through the lipophilic stratum corneum into the dermis.
As a matrikine mimic, Palmitoyl Tripeptide-38 activates fibroblast receptors to simultaneously upregulate collagen I, collagen II, collagen IV, fibronectin, hyaluronic acid, and laminin-5. This broad ECM stimulation is intended to restore the full structural and hydration network of the aging dermis rather than targeting a single component. The palmitoyl chain is essential for penetration through the epidermal barrier.
Palmitoyl Tripeptide-38 is well tolerated as an OTC cosmetic ingredient approved globally including in the EU and US. Regulatory safety assessments confirm its safety at standard cosmetic concentrations. Rare mild skin irritation and uncommon redness have been reported, typically resolving without intervention. No prescription is required, and no serious adverse events have been documented in the published cosmetic safety literature.
A 2-month vehicle-controlled clinical study at 2 percent concentration showed up to 31 percent reduction in wrinkle depth by profilometry. In vitro studies confirm simultaneous stimulation of all six target ECM proteins. However, as of 2026, no independent randomized controlled trials exist — published efficacy data are primarily manufacturer-sponsored. The simultaneous six-target mechanism is theoretically advantageous but requires independent replication.
Research references
- A serum containing vitamins C & E and a matrix-repair tripeptide reduces facial signs of aging: A double-blind, randomized, controlled studyPubMed
- A new matrikine-derived peptide up-regulates longevity genes for improving extracellular matrix architecture and skin anti-agingPubMed
- An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial SkinPubMed